A Thought Partner in Strategic Medical affairs

AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer.

Notwithstanding political ‘hiccups,’ the US will remain the most favored market for Nordic life science companies, say experts.

VTT Technical Research Centre of Finland has opened a new pilot line environment for medical devices in Oulu, Finland.

Xbrane Biopharma has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees and laboratory equipment, to Alvotech for a total consideration of approximately SEK 275 million.

The President and CEO of Camurus, Fredrik Tiberg, has been named the winner of The Arthur D. Little Nordic Life Science Award.

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product.